Revenue grew about 24% to $129.7 million. The Street estimated $127.4 million.
For Q2, the company expects an adjusted loss of $0.25 to $0.27 per basic share on revenue of $125.5 million to $126.5 million, against the Street's estimates of a $0.20 loss on revenue of $127.7 million.
For 2022, it projects an adjusted loss of $0.67 to $0.71 per basic share on revenue of $534 million to $536 million, compared with the market consensus of a $0.75 loss on revenue of $532.8 million.
The stock plunged more than 10% in after-hours trading.
Price: 87.1, Change: -6.98, Percent Change: -7.42
|Sierra Oncology Shareholders Approve Acquisition by GSK|
|Insider Sell: Factset Research Systems|
|Insider Sell: Liberty Global|
|Update: Hyperfine President, CEO to Quit; Temporary ...|
|--S&P Revises Cinemark Holdings Outlook To Positive ...|